116 related articles for article (PubMed ID: 27980745)
1. A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma.
Wallace N; Wong E; Cooper D; Chao H
Clin Case Rep; 2016 Dec; 4(12):1120-1121. PubMed ID: 27980745
[TBL] [Abstract][Full Text] [Related]
2. Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience.
Khalid S; Yasar S; Khalid A; Spiro TP; Haddad A; Daw H
Cureus; 2018 May; 10(5):e2701. PubMed ID: 30062075
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,
Chu Y; Lee S; Shah T; Yin C; Barth M; Miles RR; Ayello J; Morris E; Harrison L; Van de Ven C; Galardy P; Goldman SC; Lim MS; Hermiston M; McAllister-Lucas LM; Giulino-Roth L; Perkins SL; Cairo MS
Oncoimmunology; 2019; 8(1):e1512455. PubMed ID: 30546948
[TBL] [Abstract][Full Text] [Related]
4. Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib.
Okamoto K; Proia LA; Demarais PL
Case Rep Infect Dis; 2016; 2016():4642831. PubMed ID: 27703818
[No Abstract] [Full Text] [Related]
5. Ibrutinib: a new targeted therapy for hematologic cancers.
Smithson CR; Schneider SM
Clin J Oncol Nurs; 2015 Jun; 19(3):E47-51. PubMed ID: 26000590
[TBL] [Abstract][Full Text] [Related]
6. Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.
Papanota AM; Ntanasis-Stathopoulos I; Kastritis E; Dimopoulos MA; Gavriatopoulou M
J Blood Med; 2019; 10():291-300. PubMed ID: 31695539
[TBL] [Abstract][Full Text] [Related]
7. Profound Sinoatrial Arrest Associated with Ibrutinib.
Mathur K; Saini A; Ellenbogen KA; Shepard RK
Case Rep Oncol Med; 2017; 2017():7304021. PubMed ID: 29375920
[TBL] [Abstract][Full Text] [Related]
8. HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom's Macroglobulinemia.
Wallace MR
Case Rep Infect Dis; 2020; 2020():6516037. PubMed ID: 32274227
[TBL] [Abstract][Full Text] [Related]
9. Reversible Systolic Heart Failure in a Patient on Ibrutinib Chemotherapy.
Khaja M; Gurjar H; Yapor L; Abraham MC; Hernandez N; Haider A
Cureus; 2022 Mar; 14(3):e23266. PubMed ID: 35449638
[TBL] [Abstract][Full Text] [Related]
10. Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib.
Sun K; Kasparian S; Iyer S; Pingali SR
Ecancermedicalscience; 2018; 12():836. PubMed ID: 29910833
[TBL] [Abstract][Full Text] [Related]
11. Paronychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report.
Yorulmaz A; Yalcin B
Skin Appendage Disord; 2020 Jan; 6(1):32-36. PubMed ID: 32021859
[TBL] [Abstract][Full Text] [Related]
12. Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases.
Tafesh ZH; Coleman M; Fulmer C; Nagler J
Case Rep Gastroenterol; 2019; 13(2):357-363. PubMed ID: 31607836
[TBL] [Abstract][Full Text] [Related]
13. Serositis causing pericardial and pleural effusions after eight years of maintenance ibrutinib for Waldenstrom's macroglobulinemia.
Johnson G; Baviriseaty N; Massanet N; Kooper J
J Oncol Pharm Pract; 2023 Apr; ():10781552231171925. PubMed ID: 37097903
[TBL] [Abstract][Full Text] [Related]
14. Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Varma G; Johnson TP; Advani RH
Clin Adv Hematol Oncol; 2016 Jul; 14(7):543-54. PubMed ID: 27379948
[TBL] [Abstract][Full Text] [Related]
15. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
Wu J; Zhang M; Liu D
Oncotarget; 2017 Jan; 8(4):7201-7207. PubMed ID: 27776353
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous Iliopsoas Muscle Hemorrhage Secondary to Ibrutinib (Imbruvica; Pharmacyclics): Brief Report.
Sarcon A; Botta GP; Patel N; Saven A
J Investig Med High Impact Case Rep; 2016; 4(2):2324709616648457. PubMed ID: 27231694
[TBL] [Abstract][Full Text] [Related]
17. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
18. Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2.
Barbarino V; Henschke S; Blakemore SJ; Izquierdo E; Michalik M; Nickel N; Möllenkotte I; Vorholt D; Müller L; Brinker R; Fedorchenko O; Mikhael N; Seeger-Nukpezah T; Hallek M; Pallasch CP
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824276
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs).
Faust A; Bäumer N; Schlütermann A; Becht M; Greune L; Geyer C; Rüter C; Margeta R; Wittmann L; Dersch P; Lenz G; Berdel WE; Bäumer S
Angew Chem Int Ed Engl; 2022 Jan; 61(1):e202109769. PubMed ID: 34725904
[TBL] [Abstract][Full Text] [Related]
20. Idelalisib in a patient with refractory Waldenström's macroglobulinemia complicated by anuric renal failure: a case report.
D'Aveni-Piney M; Divoux M; Busby-Venner H; Muller M; Broséus J; Feugier P
J Med Case Rep; 2018 Jun; 12(1):164. PubMed ID: 29890999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
